GO
Loading...

Enter multiple symbols separated by commas

Eli Lilly and Co

More

  • Indiana governor signs fix to religion bill Thursday, 2 Apr 2015 | 6:30 PM ET
    Indiana House Speaker Brian Bosma speaks at the State Capitol April, 2, 2015 in Indianapolis.

    Businesses and groups have been reacting to a legislative fix to Indiana's Religious Freedom Restoration Act on Thursday.

  • *Novo to submit interim trial data for Tresiba with FDA. The drug was rebuffed by the FDA two years ago. Citigroup's Peter Verdult said he believed the odds of U.S. approval were greater than 90 percent, given a small group of Novo staff sitting behind a communications "firewall" had already discussed the data with FDA.

  • March 23- The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths. The FDA said its investigation into the deaths was inconclusive. It carries a boxed warning, FDA's most serious type of warning, for post-injection delirium sedation or olanzapine...

  • March 23- The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths. Elevated levels of the drug, Zyprexa Relprevv, were found in the two patients who died three to four days after receiving the injection. The FDA said its investigation into the deaths was...

  • March 23- Pfizer Inc and Eli Lilly and Co will resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it. Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday. In 2013, Pfizer forged a deal with Lilly to jointly develop...

  • March 23- Pfizer Inc and Eli Lilly and Co said they planned to resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it. Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday. The FDA put tanezumab and all other...

  • Biogen takes aim at Alzheimer's, ALS drugs Monday, 23 Mar 2015 | 6:48 AM ET
    A multiple sclerosis drug manufactured at the Biogen Idec manufacturing plant in Cambridge, Mass.

    Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.

  • March 20- An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with...

  • Biogen Alzheimer's drug shows promise, shares up Friday, 20 Mar 2015 | 11:05 AM ET
    A multiple sclerosis drug manufactured at the Biogen Idec manufacturing plant in Cambridge, Mass.

    A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.

  • March 20- An experimental drug from Biogen Idec became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with expensive...

  • Moment of truth for Biogen's big Alzheimer's bet Thursday, 19 Mar 2015 | 12:55 PM ET
    alzheimer's

    As Biogen Idec gets set to reveal new data on its Alzheimer's drug, BIIB037, investors should be prepared for a big move either way.

  • LONDON, March 17- Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss. Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60- year-old Lars Sorensen,...

  • *Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by Britain's health minister Jeremy Hunt at a meeting in Geneva on Tuesday, follows a Group of Eight nations conference in London in December 2013 that set a goal of finding a...

  • LONDON, March 17- The world's first venture capital fund dedicated to finding new ways to prevent and treat dementia has raised $100 million with the backing of the British government and several of the world's leading drugmakers. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by...

  • LONDON, March 14- Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday. The finding may boost sales of the blood-thinner, which AstraZeneca is relying on to drive growth, although doctors must balance its...

  • Why biotech investors may be hurting innovation Friday, 13 Mar 2015 | 3:27 PM ET
    Biotech

    Over the past five years, investor money is increasingly moving toward consumer software and later-stage life science ventures, a trend that could help develop new treatments.

  • March 4- Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching. It affects between 9 and 30 percent of the U.S. population, according to the National Institutes of Health. The company regained the U.S. and Canada rights for its schizophrenia drug Fanapt from Novartis AG late last year.

  • The number of men being prescribed testosterone jumped more than 75 percent, to 2.3 million, between 2009 and 2013. About 70 percent of these patients were between the ages of 40 and 64, the FDA said. AbbVie Inc's AndroGel, one of the most widely-used products, raked in sales of $934 million in 2014. Other products include Endo International Plc's Testim and Eli...

  • LONDON, March 2- GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis.

  • Feb 26- Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult. Sanofi shares were 1 percent lower at 88.20 euros by 1029 GMT. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co to keep a cheaper Lantus generic off the market...